Discontinued — last reported Q4 '16
Business Segments · Goodwill Adjustments
Diagnostics And Genomics — Goodwill Adjustments
Year-over-year, this metric grew by 100.0%, from -$1.00M to $0.00.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ4 2016
How to read this metric
An increase indicates significant recent acquisition activity or currency volatility affecting the segment's balance sheet, while a decrease suggests stability in acquisition-related accounting.
Detailed definition
This metric represents the non-cash adjustments to goodwill and intangible assets within the Diagnostics and Genomics se...
Peer comparison
Similar to 'Goodwill and Intangible Asset Adjustments' found in the segment reporting notes of other life sciences and diagnostics peers.
Metric ID:
a_segment_diagnostics_and_genomics_goodwill_translation_and_purchase_accounting_adjustmentsHistorical Data
11 periods
| Q1 '21 | Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$1.00M | -$3.00M | -$4.00M | -$3.00M | $1.00M | $1.00M | -$1.00M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | -200.0% | -33.3% | +25.0% | +133.3% | +0.0% | -200.0% | +100.0% | — | — |
| YoY Change | — | — | — | — | -200.0% | +133.3% | +125.0% | +66.7% | -100.0% | -100.0% | +100.0% |
Range-$4.00M – $1.00M
Avg YoY Growth+3.6%
Median YoY Growth+66.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's diagnostics and genomics — goodwill adjustments?
- Agilent Technologies (A) reported diagnostics and genomics — goodwill adjustments of $0.00 in Q2 2024.
- How has Agilent Technologies's diagnostics and genomics — goodwill adjustments changed year-over-year?
- Agilent Technologies's diagnostics and genomics — goodwill adjustments increased by 100.0% year-over-year, from -$1.00M to $0.00.
- What does diagnostics and genomics — goodwill adjustments mean?
- The non-cash accounting adjustments to asset values in the Diagnostics and Genomics segment due to acquisitions and currency fluctuations.